Table 3.
Comparison of clinical and H3K27M-status in personalized and control cohort.
| Personalized | Control | |
|---|---|---|
| Age in years, median (range) | 6.6 (4.8–19) | 8.2 (2.4–11.1) |
| Gender (m:f) | 4:5 | 6:3 |
| Localization | ||
| Pons | 7 | 8 |
| Thalamus | 1 | 1 |
| Spinal | 1 | – |
| H3K27M detection | ||
| H3F3A | 7 | 4 |
| HISTH3B | 2 | 1 |
| IHC | 0 | 4 |
| Backbone treatment (first line) | ||
| Nimotuzumab/vinorelbine | 6 | 4 |
| Temozolomide | 3 | 4 |
| Other | 0 | 1 |
IHC, immunohistochemistry.